Experimental Alzheimer's Drug Shows Promise in Delaying Symptoms
Scientists report that long-term use of gantenerumab might prevent cognitive decline in people with genetic predisposition to early-onset Alzheimer's.
Archive context
Older archive item. Useful for background and entity history, but not a fresh market-moving signal.
Why this matters
This cryptocurrency story adds another data point to the current market tape and is useful when read alongside nearby source coverage.
Original source
Read on DecryptRelated market context
Bitcoin price hits $69,500 because US just doubled Treasury buybacks to crush long-term yields
Bitcoin and Ethereum surged above $69,500 and $2,000 on Wednesday after the US Treasury doubled planned buybacks of long-dated gov...
Strategy reports $1.2B increase in MSTR positions from top shareholders in Q2
Institutional confidence in Bitcoin-linked assets remains strong, signaling potential long-term bullish sentiment despite slowing...
Solana leads in tokenized stock deposits on DeFi platforms: report
Solana's DeFi prominence may boost its ecosystem, but varied market expectations suggest uncertainty in its near-term price trajec...
Galaxy reports $11B decline in crypto-collateralized lending in Q2 2026
The decline in crypto-collateralized lending suggests a cautious market recalibration, potentially stabilizing the sector and fost...
Agentic AI needs a governance layer, and blockchain might be the answer
Blockchain's integration as a governance layer for autonomous AI could enhance accountability, identity management, and transactio...
Centrifuge reports 300% growth in tokenized assets to nearly $4B
Centrifuge's growth highlights tokenization's potential to bridge traditional finance and DeFi, offering stability amid crypto vol...